Latest News about GSK
Recent news which mentions GSK
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
September 02, 2022
From Benzinga
Novartis Appoints Merck Executive As Research Head
September 01, 2022
From Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
From Benzinga
IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate
August 29, 2022
From Benzinga
3 Dependable Stocks With Dividend Yields Above 5%
August 24, 2022
From Motley Fool
The Rise and Fall of Novavax
August 21, 2022
From Motley Fool
Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
August 18, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
August 18, 2022
From Benzinga
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
August 17, 2022
From Benzinga
One Suit Down Out Of 3,000 Zantac Related Lawsuits, Says GSK
August 17, 2022
Tickers
GSK
From Benzinga
From MarketWatch
Why IDEAYA Biosciences Shares Plunging Today
August 15, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Monday
August 15, 2022
From Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
August 15, 2022
From Benzinga
Do I Need to Get A Polio Vaccine? New York Sewer Discovery Triggers Fears About Paralysis-Inducing Virus
August 12, 2022
From Benzinga
GSK defends Zantac ahead of trials that have cratered the stock
August 12, 2022
From MarketWatch
Why Pfizer Stock Slipped Today
August 11, 2022
From Motley Fool
Why GSK Is So Deep in the Red Today
August 11, 2022
From Motley Fool
Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
August 11, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
August 11, 2022
From Benzinga
GSK, PFE, SNY Stocks Fall on Zantac Litigation
August 11, 2022
From InvestorPlace
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
August 10, 2022
From Benzinga
From Benzinga
From Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
From Benzinga
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
August 09, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.